stoxline Quote Chart Rank Option Currency Glossary
  
Jaguar Health, Inc. (JAGX)
4.53  0.27 (6.34%)    05-22 16:00
Open: 4.33
High: 4.5499
Volume: 68,842
  
Pre. Close: 4.26
Low: 4.38
Market Cap: 5(M)
Technical analysis
2025-05-22 3:48:33 PM
Short term     
Mid term     
Targets 6-month :  13.07 1-year :  18.08
Resists First :  11.19 Second :  15.47
Pivot price 7.74
Supports First :  4.26 Second :  3.54
MAs MA(5) :  5.25 MA(20) :  8.69
MA(100) :  13.82 MA(250) :  33.28
MACD MACD :  -1 Signal :  -0.5
%K %D K(14,3) :  3.2 D(3) :  4.6
RSI RSI(14): 33.5
52-week High :  132.5 Low :  0.82
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ JAGX ] has closed above bottom band by 20.0%. Bollinger Bands are 3.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.31 - 5.34 5.34 - 5.36
Low: 4.2 - 4.23 4.23 - 4.25
Close: 4.22 - 4.26 4.26 - 4.3
Company Description

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Headline News

Wed, 21 May 2025
Jaguar Health (JAGX) Announces Direct Offering and Private Placement | JAGX Stock News - GuruFocus

Wed, 21 May 2025
Jaguar Health Prices Offering of Shares, Warrants - marketscreener.com

Wed, 21 May 2025
Jaguar Health Secures Fresh Capital: $1.5M Direct Offering Plus Warrants - Key Terms Revealed - Stock Titan

Wed, 21 May 2025
SEC Form 424B5 filed by Jaguar Health Inc. - Quantisnow

Tue, 20 May 2025
First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID) - Yahoo Finance

Mon, 19 May 2025
JAGX: Jaguar Health Coverage Initiated with Buy Rating | JAGX Stock News - GuruFocus

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 12.7 (%)
Held by Institutions 1.5 (%)
Shares Short 53 (K)
Shares Short P.Month 36 (K)
Stock Financials
EPS -130.7
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 13.78
Profit Margin 0 %
Operating Margin -232.5 %
Return on Assets (ttm) -37 %
Return on Equity (ttm) -565.8 %
Qtrly Rev. Growth 52.5 %
Gross Profit (p.s.) 14.43
Sales Per Share 17.34
EBITDA (p.s.) -42.93
Qtrly Earnings Growth 0 %
Operating Cash Flow -29 (M)
Levered Free Cash Flow -19 (M)
Stock Valuations
PE Ratio -0.04
PEG Ratio 0
Price to Book value 0.32
Price to Sales 0.26
Price to Cash Flow -0.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android